April 26, 2018 / 6:32 AM / 5 months ago

BRIEF-Roche Holding AG CEO Says Very Confident We Can Grow In Spite Of The Entry Of Biosimilars

April 26 (Reuters) - Roche Holding AG:

* CEO SAYS CONFIDENT OF ROCHE’S ABILITY TO CONTINUE GROWTH BEYOND 2018 DESPITE BIOSIMILAR ENTRIES

* CEO SAYS INCREASE IN GUIDANCE IS FOR BOTH SALES AND EPS

* DRUG DIVISION CHIEF SAYS RITUXAN DECLINE IN EUROPE WAS BROADLY EXPECTED, SEES EUROPEAN EROSION TO CONTINUE IN SECOND HALF OF YEAR COUPLED WITH ARRIVAL OF FIRST HERCEPTIN COPY

* DRUG DIVISION CHIEF SAYS STILL CONFIDENT CAN COMPENSATE FOR BIOSIMILAR EROSION OF OLDER DRUGS

* DRUG DIVISION CHIEF SEES CONTINUED STRONG OCREVUS GROWTH

* CEO SAYS WE ARE ON THE CONSTANT LOOKOUT FOR NEW TECHNOLOGIES, WE SCREEN THE MARKET FOR OPPORTUNITIES

* CEO SAYS CONTINUES TO LOOK FOR BOLT-ON ACQUISITIONS

* CEO SAYS TYPICALLY DOES NOT MAKE SENSE TO PURSUE LATE-STAGE TRANSACTIONS THAT END UP IN BIDDING PROCESS, CLEARLY HAS FOCUS ON EARLIER STAGE ASSETS

* CEO SAYS HAS 15 NEW MOLECULAR ENTITITES IN LATE STAGE PORTFOLIO

* CEO SAYS VERY CONFIDENT WE CAN GROW IN SPITE OF THE ENTRY OF BIOSIMILARS Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below